Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 1112 (2021)

Trends of incidence, mortality and survival for chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland between 1997 and 2016: a population-based study

DOI
https://doi.org/10.4414/smw.2021.20463
Cite this as:
Swiss Med Wkly. 2021;151:w20463
Published
15.03.2021

Summary

BACKGROUND

During the last 20 years, treatment for chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) has advanced, with improved clinical outcomes in randomised controlled trials. Currently, no data have been published from Switzerland to assess effectiveness of recent healthcare advances in CLL/SLL on a population-based level. We aimed to estimate trends in incidence, mortality and survival for patients with CLL/SLL in Switzerland.

METHODS

We retrospectively studied registry data from the National Agency for Cancer Registration (NACR) database in Switzerland from 1997 to 2016. We investigated incidence, mortality and survival in consecutive 5-year periods. Age-specific rates were calculated for three age groups (<65 years, 65–74 years and ≥75 years).

RESULTS

We obtained 6301 cases with CLL/SLL. Median age at diagnosis was 72 years. From 7.0 per 100,000 person-years in 1997–2002, age-adjusted incidence rates peaked at 7.8 per 100,000 person-years in the second time period, 2002–2006, and declined afterwards to 6.4 per 100,000 person-years in 2012–2016. Mortality declined from 2.4 per 100,000 person-years in 1997–2002 to 2.0 per 100,000 in 2012–2016. Five- and 10-year age-standardised relative survival increased from 77.9% and 55.6%, respectively, in 1997–2001 to 83.6% (p = 0.009) and 64.2% (p = 0.005), respectively, in 2012–2016. Improvement in age-specific relative survival was only significant in the middle age group (65–74 years). Incidence and mortality were significantly higher in males. Females had better relative survival.

CONCLUSION

We found no clear down- or upward trend in age-adjusted incidence rates. Age-standardised survival improved over time, mainly in the two younger age-groups, but this improvement was statistically significant in those aged 65–74 years only. Males have higher incidence rates, higher mortality and shorter survival than females. Reporting delay and underreporting are major limitations in the interpretation of registry data from patients diagnosed with CLL/SLL.

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. ed: International Agency for Research on Cancer; 2017.
  2. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute Bethesda, MD: National Cancer Institute; 2018 [updated April 2018; cited 2018 November 2]. Available from: https://seer.cancer.gov/csr/1975_2015/.
  3. Santos FPS O’Brien S. Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease? Cancer J. 2012;18(5):396–403. doi:.https://doi.org/10.1097/PPO.0b013e31826cda2d
  4. Kipps TJ Stevenson FK Wu CJ Croce CM Packham G Wierda WG Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3(1):16096. doi:.https://doi.org/10.1038/nrdp.2016.96
  5. Hallek M Shanafelt TD Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524–37. doi:.https://doi.org/10.1016/S0140-6736(18)30422-7
  6. Grever MR Kopecky KJ Coltman CA Files JC Greenberg BR Hutton JJ Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988;30(5-6):457–9.
  7. Piro LD Carrera CJ Beutler E Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988;72(3):1069–73. doi:.https://doi.org/10.1182/blood.V72.3.1069.bloodjournal7231069
  8. Keating MJ O’Brien S Albitar M Lerner S Plunkett W Giles F Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–88. doi:.https://doi.org/10.1200/JCO.2005.12.051
  9. Hallek M Fischer K Fingerle-Rowson G Fink AM Busch R Mayer J International Group of Investigators German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74. doi:.https://doi.org/10.1016/S0140-6736(10)61381-5
  10. Robak T Dmoszynska A Solal-Céligny P Warzocha K Loscertales J Catalano J Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–65. doi:.https://doi.org/10.1200/JCO.2009.26.4556
  11. Goede V Fischer K Busch R Engelke A Eichhorst B Wendtner CM Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. doi:.https://doi.org/10.1056/NEJMoa1313984
  12. Eichhorst B Fink A-M Bahlo J Busch R Kovacs G Maurer C international group of investigators German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42. doi:.https://doi.org/10.1016/S1470-2045(16)30051-1
  13. Byrd JC Furman RR Coutre SE Flinn IW Burger JA Blum KA Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi:.https://doi.org/10.1056/NEJMoa1215637
  14. Furman RR Sharman JP Coutre SE Cheson BD Pagel JM Hillmen P Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. doi:.https://doi.org/10.1056/NEJMoa1315226
  15. Seymour JF Kipps TJ Eichhorst B Hillmen P D’Rozario J Assouline S Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(12):1107–20. doi:.https://doi.org/10.1056/NEJMoa1713976
  16. da Cunha-Bang C Simonsen J Rostgaard K Geisler C Hjalgrim H Niemann CU. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016;6(11):e499. doi:.https://doi.org/10.1038/bcj.2016.105
  17. Lenartova A Johannesen TB Tjønnfjord GE. National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data. Cancer Med. 2016;5(12):3588–95. doi:.https://doi.org/10.1002/cam4.849
  18. Pulte D Castro FA Jansen L Luttmann S Holleczek B Nennecke A GEKID Cancer Survival Working Group. Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. J Hematol Oncol. 2016;9(1):28. doi:.https://doi.org/10.1186/s13045-016-0257-2
  19. Arndt V. Population-based cancer registration and research in Switzerland: examples, limitations and perspectives. Swiss Cancer Bulletin. 2016;36(4):354–9.
  20. World Health Organization. International statistical classification of diseases and related health problems. 10th revision, Fifth edition, 2016 ed. Geneva: World Health Organization; 2015.
  21. Pace M, Cayotte E, Agafitei L, Zupanic T, Wojtyniak B, Gissler M, et al. Revision of the European Standard Population: report of Eurostat's task force: 2013 edition. Luxembourg: Publications Office; 2013.
  22. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. GPE Discussion Paper Series: No. 31. Age standardization of rates: a new WHO standard. World Health Organization; 2000.
  23. Dickman PW Coviello E. Estimating and modeling relative survival. Stata J. 2015;15(1):186–215. doi:.https://doi.org/10.1177/1536867X1501500112
  24. Hockey R Tooth L Dobson A. Relative survival: a useful tool to assess generalisability in longitudinal studies of health in older persons. Emerg Themes Epidemiol. 2011;8(1):3. doi:.https://doi.org/10.1186/1742-7622-8-3
  25. Corazziari I Quinn M Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40(15):2307–16. doi:.https://doi.org/10.1016/j.ejca.2004.07.002
  26. Parkin D, Hakulinen T. Analysis of Survival. Cancer Registration: Principles and Methods. Lyon: International Agency for Research on Cancer (IACR); 1991. p. 159-76.
  27. Cancer Incidence in Five Continents. CI5plus: IARC CancerBase No. 9 [Internet]. International Agency for Research on Cancer. 2018. Available from: http://ci5.iarc.fr
  28. van den Broek EC Kater AP van de Schans SAM Karim-Kos HE Janssen-Heijnen MLG Peters WG Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989-2008. Eur J Cancer. 2012;48(6):889–95. doi:.https://doi.org/10.1016/j.ejca.2011.06.053
  29. Nennecke A Wienecke A Kraywinkel K. Inzidenz und Überleben bei Leukämien in Deutschland nach aktuellen standardisierten Kategorien [Leukemia incidence and survival in Germany according to current standardized categories]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(1):93–102. Article in German. doi:.https://doi.org/10.1007/s00103-013-1869-0
  30. Dores GM Anderson WF Curtis RE Landgren O Ostroumova E Bluhm EC Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139(5):809–19. doi:.https://doi.org/10.1111/j.1365-2141.2007.06856.x
  31. Lorez M Bordoni A Bouchardy C Bulliard J-L Camey B Dehler S Evaluation of completeness of case ascertainment in Swiss cancer registration. Eur J Cancer Prev. 2017;26:S139–46. doi:.https://doi.org/10.1097/CEJ.0000000000000380
  32. Hallek M Cheson BD Catovsky D Caligaris-Cappio F Dighiero G Döhner H International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56. doi:.https://doi.org/10.1182/blood-2007-06-093906
  33. Hallek M Cheson BD Catovsky D Caligaris-Cappio F Dighiero G Döhner H iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60. doi:.https://doi.org/10.1182/blood-2017-09-806398
  34. Catovsky D Wade R Else M. The clinical significance of patients’ sex in chronic lymphocytic leukemia. Haematologica. 2014;99(6):1088–94. doi:.https://doi.org/10.3324/haematol.2013.101378
  35. Allain EP Venzl K Caron P Turcotte V Simonyan D Gruber M Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. Ann Hematol. 2018;97(9):1649–61. doi:.https://doi.org/10.1007/s00277-018-3356-z
  36. Carè A Bellenghi M Matarrese P Gabriele L Salvioli S Malorni W. Sex disparity in cancer: roles of microRNAs and related functional players. Cell Death Differ. 2018;25(3):477–85. doi:.https://doi.org/10.1038/s41418-017-0051-x
  37. Lin S Liu Y Goldin LR Lyu C Kong X Zhang Y Sex-related DNA methylation differences in B cell chronic lymphocytic leukemia. Biol Sex Differ. 2019;10(1):2. doi:.https://doi.org/10.1186/s13293-018-0213-7
  38. List of authorised medicines: Swissmedic. Swiss Agency for Therapeutic Products; 2020 [updated 2020 October 31; cited 2020 November 30]. Available from: https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/zugelassene_arzneimittel_ham.xlsx.download.xlsx/Zugelassene_Arzneimittel_HAM.xlsx.
  39. PharmaWiki. Medikamente und Gesundheit: PharmaWiki GmbH; [cited 2020 November 30]. Available from: https://www.pharmawiki.ch/wiki/.
  40. Shanafelt TD Wang XV Kay NE Hanson CA O’Brien S Barrientos J Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019;381(5):432–43. doi:.https://doi.org/10.1056/NEJMoa1817073

Most read articles by the same author(s)